We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-18.55%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.33B
AUM Growth
-$894M
Cap. Flow
-$130M
Cap. Flow %
-5.55%
Top 10 Hldgs %
69.04%
Holding
126
New
9
Increased
16
Reduced
12
Closed
23

Top Buys

Rank Stock Value
1
NMRA icon
Neumora Therapeutics
NMRA
+$35M
2
APLS
Apellis Pharmaceuticals
APLS
+$27M
3
SLRN
ACELYRIN
SLRN
+$13.8M
4
IMGN
Immunogen Inc
IMGN
+$12.4M
5
SGMT icon
Sagimet Biosciences
SGMT
+$12.3M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$41.1M
2
SAGE
Sage Therapeutics
SAGE
+$23.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.4M
4
RLAY icon
Relay Therapeutics
RLAY
+$15.2M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 54.42%
2 Consumer Discretionary 42.85%
3 Technology 0.61%
4 Communication Services 0.19%
5 Real Estate 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
51
Dyne Therapeutics
DYN
$4.15B
$7.3M 0.31%
815,085
– –
DAWN
52
DELISTED
Day One Biopharmaceuticals
DAWN
$6.13M 0.26%
500,000
– –
FOLD
53
CALL
DELISTED
Amicus Therapeutics
FOLD
$6.08M 0.26%
500,000
– –
BDTX icon
54
Black Diamond Therapeutics
BDTX
$95.1M
$5.87M 0.25%
2,046,517
– –
SYRS
55
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.83M 0.25%
1,475,744
– –
VOR icon
56
Vor Biopharma
VOR
$1.06B
$5.7M 0.24%
134,401
– –
OMGA
57
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$5.45M 0.23%
2,533,045
– –
GOSS icon
58
Gossamer Bio
GOSS
$101M
$5.33M 0.23%
6,399,819
+3,371,648
+111% +$3.89M
FUSN
59
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$4.49M 0.19%
1,725,000
– –
ITOS
60
DELISTED
iTeos Therapeutics
ITOS
$4.38M 0.19%
400,000
– –
BEKE icon
61
KE Holdings
BEKE
$17.7B
$4.27M 0.18%
275,000
-75,000
-21% -$1.19M
VERV
62
DELISTED
Verve Therapeutics
VERV
$3.98M 0.17%
300,000
– –
HOOK
63
DELISTED
HOOKIPA Pharma
HOOK
$3.49M 0.15%
566,641
– –
BZ icon
64
Kanzhun
BZ
$7.19B
$3.34M 0.14%
220,000
– –
TRML
65
DELISTED
Tourmaline Bio
TRML
$2.57M 0.11%
91,426
– –
SLDB icon
66
Solid Biosciences
SLDB
$792M
$2.29M 0.1%
909,219
– –
ACHL
67
DELISTED
Achilles Therapeutics
ACHL
$2.05M 0.09%
2,255,375
– –
KRON
68
DELISTED
Kronos Bio
KRON
$2.01M 0.09%
1,542,954
– –
RNAM
69
DELISTED
Avidity Biosciences
RNAM
$1.91M 0.08%
300,000
– –
PYPL icon
70
CALL
PayPal
PYPL
$50.3B
$1.87M 0.08%
+32,000
New +$2.08M
MSFT icon
71
Microsoft
MSFT
$2.9T
$1.74M 0.07%
5,500
+2,500
+83% +$826K
V icon
72
Visa
V
$701B
$1.73M 0.07%
7,500
– –
ADAG
73
Adagene
ADAG
$246M
$1.53M 0.07%
1,000,000
– –
AMZN icon
74
Amazon
AMZN
$2.44T
$1.52M 0.07%
12,000
+2,000
+20% +$268K
NBP
75
NovaBridge Biosciences American Depositary Shares
NBP
$186M
$1.12M 0.05%
850,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2023 Portfolio in Review

As of Q3 2023, Artal Group held 126 positions worth $2.33B, down 28% from $3.23B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group withdrew a net $130M in Q3 2023, closing 23 positions and reducing 12 holdings. Its most notable exit was Krystal Biotech, an estimated $41.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 55% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Neumora Therapeutics worth $39.5M.

  • Artal Group's largest Q3 2023 buy was Neumora Therapeutics: 2,802,702 shares worth $39.5M.
  • Artal Group added most to Apellis Pharmaceuticals in Q3 2023, an estimated $27M increase.
  • Artal Group's biggest Q3 2023 reduction was Schrodinger, cutting an estimated $8.06M.
  • Artal Group fully exited Krystal Biotech in Q3 2023, selling an estimated $41.1M.
  • Artal Group's ten largest holdings make up 69% of its $2.33B portfolio in Q3 2023.
  • Artal Group opened 9 new positions and closed 23 in Q3 2023.
  • Artal Group's portfolio value fell 28% quarter-over-quarter to $2.33B.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.